Skip to Content

Immuron Ltd ADR IMRN

Morningstar Rating
$2.46 −0.14 (5.44%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

IMRN is trading at a 48% discount.
Price
$2.61
Fair Value
$3.69
Uncertainty
Extreme
1-Star Price
$33.52
5-Star Price
$8.89
Economic Moat
Qqt
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IMRN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.60
Day Range
$2.462.57
52-Week Range
$1.485.96
Bid/Ask
$2.50 / $2.57
Market Cap
$14.01 Mil
Volume/Avg
1,889 / 1.0 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
6.24
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
6

Valuation

Metric
IMRN
Price/Earnings (Normalized)
Price/Book Value
1.24
Price/Sales
6.24
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
IMRN
Quick Ratio
7.63
Current Ratio
8.52
Interest Coverage
−446.38
Quick Ratio
IMRN

Profitability

Metric
IMRN
Return on Assets (Normalized)
−17.91%
Return on Equity (Normalized)
−19.92%
Return on Invested Capital (Normalized)
−20.86%
Return on Assets
IMRN
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRNhpcyxqbnxTqyr$557.8 Bil
VRTX
Vertex Pharmaceuticals IncQkxsyvxpXmlfcy$103.3 Bil
REGN
Regeneron Pharmaceuticals IncJzkpxxyZpzjjw$98.8 Bil
MRNA
Moderna IncSdgldnnWhc$38.8 Bil
ARGX
argenx SE ADRCkxgmdlpFwzfm$21.3 Bil
BNTX
BioNTech SE ADRHnptftgGfczq$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncMfllzjrmzLhdwdnb$18.4 Bil
BMRN
Biomarin Pharmaceutical IncCtytdbgdBmjsmy$17.0 Bil
RPRX
Royalty Pharma PLC Class AMfjzbmcnjFbxyd$12.4 Bil
INCY
Incyte CorpQfsnvmvkWhlcgn$11.9 Bil

Sponsor Center